Illumina Launches More Accurate and Comprehensive Secondary Analysis Platform to Empower Laboratory Capabilities

DRAGEN^TM v4.0 Bringing unprecedented precision, workflow richness, and efficiency to genomic analysis, fully unlocking the potential of genomics to improve human health.

San Diego, California, USAJuly 28, 2022PR Newswire -- July 27, 2022, Illumina (NASDAQ: ILMN), a global leader in gene sequencing and microarray technologies, announced the launch of a more accurate and comprehensive secondary analysis platform.-- Illumina DRAGEN™v4.0. The new features expand the laboratory's ability to analyze key areas such as oncology, pharmacogenomics (PGx), single-cell sequencing, and population genomics on a single platform.

Chief Technology Officer of Illumina, Head of Research and Product DevelopmentAlex Aravanis"Innovation is the core driving force behind all of Illumina's actions. With the launch of the more comprehensive, precise, and efficient DRAGEN v4.0, we are committed to providing customers with unparalleled versatility and functionality."

Illumina DRAGEN is a leading secondary analysis software in the field of genomics, and its continuous innovation has set new standards for the accuracy and efficiency of sequencing analysis. DRAGEN can be utilized through various configuration options. Currently, Illumina offers customers multiple solutions ranging from standalone servers to Illumina's cloud-based solutions and onboard sequencer options, streamlining the process of obtaining and analyzing sequencing data.

DRAGEN v4.0 offers customers an expanded set of features, empowering them to unlock the potential of genomics:

Illumina, Inc. expects the latest DRAGEN technology to help customers improve research efficiency and accuracy. Scientific Director of Cardio-CAREAndreas Ziegler"We have been using DRAGEN for more than two years in the bioinformatics core team of Cardio-CARE, which has enabled us to gain a deeper understanding of the genetic basis of cardiovascular diseases. We found DRAGEN to be highly efficient and easy to use, while delivering excellent performance in the localization and alignment of single nucleotide variants and short insertions/deletions. We are looking forward to seeing how the advanced features of DRAGEN v4.0 will help us achieve our goal of improving the world's deadliest disease." -- The Promise of Diagnosing Cardiovascular Diseases and Identifying Drug Targets

VisitDRAGEN Special Topic PageLearn more.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Our business is subject to the following key factors, which could cause actual results to differ materially from those anticipated in any forward-looking statement: (i) the inherent challenges in developing, manufacturing, and launching new products and services; (ii) customer acceptance and satisfaction with new products and services; and (iii) legislative, regulatory, and economic developments, as well as other factors detailed in our filings with the U.S. Securities and Exchange Commission, including our most recent Forms 10-K and 10-Q, or information disclosed during public conference calls, for which dates and times have been announced in advance. We have no obligation to update these forward-looking statements, nor do we intend to assess or confirm analysts' related expectations, or provide interim reports or updates for the current quarter.

About Illumina

Illumina, Inc. is committed to promoting and inspiring the development of genomics while continuously improving human health. Our focus on innovation has made us a global leader in sequencing and array technologies, providing specialized services to customers in research, clinical, and applied markets worldwide. Our products are widely used in life sciences, oncology, reproductive health, agriculture, and other emerging fields. For more information, please visitwww.illumina.com.cnOr follow the Illumina WeChat Official Account.